{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:21:06Z","timestamp":1761060066082,"version":"build-2065373602"},"reference-count":76,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1016\/j.urolonc.2015.12.004","type":"journal-article","created":{"date-parts":[[2016,1,15]],"date-time":"2016-01-15T00:49:08Z","timestamp":1452818948000},"page":"279-289","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Intravesical and alternative bladder-preservation therapies in the management of non\u2013muscle-invasive bladder cancer unresponsive to bacillus Calmette-Gu\u00e9rin"],"prefix":"10.1016","volume":"34","author":[{"given":"Ryan L.","family":"Steinberg","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lewis J.","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth G.","family":"Nepple","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2015.12.004_bib1","first-page":"5","article-title":"Cancer statistics, 2015","volume":"65","author":"Siegel","year":"2015","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.urolonc.2015.12.004_bib2","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.1016\/j.juro.2007.09.003","article-title":"Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update","volume":"178","author":"Hall","year":"2007","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2015.12.004_bib3","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.eururo.2013.06.003","article-title":"EAU guidelines on non\u2013muscle-invasive urothelial carcinoma of the bladder: update 2013","volume":"64","author":"Babjuk","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2015.12.004_bib4","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/j.juro.2010.06.147","volume":"184","author":"Nepple","year":"2010","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2015.12.004_bib5","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/S0022-5347(17)43959-0","article-title":"Risks and benefits of repeated courses of intravesical Bacillus Calmette-Guerin therapy for superficial bladder cancer","volume":"137","author":"Catalona","year":"1987","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2015.12.004_bib6","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s00345-006-0112-0","article-title":"Treatment options for BCG failures","volume":"24","author":"O\u05f3Donnell","year":"2006","journal-title":"World J Urol"},{"key":"10.1016\/j.urolonc.2015.12.004_bib7","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1097\/01.ju.0000062605.92268.c6","article-title":"Defining Bacillus Calmette-Guerin refractory superficial bladder tumors","volume":"169","author":"Herr","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2015.12.004_bib8","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/nrurol.2015.58","article-title":"Expert consensus document: consensus statement on best practice management regarding the use of intravesical immunotherapy with BCG for bladder cancer","volume":"12","author":"Kamat","year":"2015","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.urolonc.2015.12.004_bib9","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1634\/theoncologist.6-1-34","article-title":"Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities","volume":"6","author":"Jonasch","year":"2001","journal-title":"Oncologist"},{"key":"10.1016\/j.urolonc.2015.12.004_bib10","doi-asserted-by":"crossref","first-page":"8973","DOI":"10.1158\/0008-5472.CAN-04-1909","article-title":"Role of tumor necrosis factor-related apoptosis-inducing ligand in interferon-induced apoptosis in human bladder cancer cells","volume":"64","author":"Papageorgiou","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.urolonc.2015.12.004_bib11","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1007\/s11934-001-0027-7","article-title":"Immunotherapy for bladder cancer","volume":"2","author":"Kamat","year":"2001","journal-title":"Curr Urol Rep"},{"key":"10.1016\/j.urolonc.2015.12.004_bib12","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1200\/JCO.1988.6.3.476","article-title":"Alpha-interferon in superficial bladder cancer: a Northern California oncology group study","volume":"6","author":"Torti","year":"1988","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2015.12.004_bib13","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/S0022-5347(17)39547-2","article-title":"A randomized controlled study of intravesical alpha-2b-interferon in carcinoma in situ of the bladder","volume":"144","author":"Glashan","year":"1990","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2015.12.004_bib14","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/1078-1439(95)00039-K","article-title":"Failure of intravesical interferon-alfa-2b for the treatment of patients with superficial bladder cancer previously failing intravesical BCG therapy","volume":"1","author":"Hudson","year":"1995","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urolonc.2015.12.004_bib15","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/S0022-5347(01)65748-3","article-title":"Mycobacterium cell wall: an alternative to intravesical bacillus Calmette Guerin (BCG) therapy in orthotopic murine bladder cancer","volume":"156","author":"Chin","year":"1996","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2015.12.004_bib16","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1093\/jnci\/55.3.727","article-title":"Immunotherapy of cancer: tumor suppression and regression by cell walls of Mycobacterium phlei attached to oil droplets","volume":"55","author":"Gray","year":"1975","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.urolonc.2015.12.004_bib17","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1002\/1097-0142(197904)43:4<1314::AID-CNCR2820430420>3.0.CO;2-6","article-title":"Adjuvant immunotherapy of lung cancer with BCG cell wall skeleton (BCG-CWS)","volume":"43","author":"Yamamura","year":"1979","journal-title":"Cancer"},{"key":"10.1016\/j.urolonc.2015.12.004_bib18","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1517\/13543784.10.12.2157","article-title":"Therapeutic potential of mycobacterial cell wall-DNA complexes","volume":"10","author":"Filion","year":"2001","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.urolonc.2015.12.004_bib19","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/sj.bjc.6690038","article-title":"Mycobacterium phlei cell wall complex directly induces apoptosis in human bladder cancer cells","volume":"79","author":"Filion","year":"1999","journal-title":"Br J Cancer"},{"key":"10.1016\/j.urolonc.2015.12.004_bib20","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s002620000121","article-title":"Modulation of interleukin-12 synthesis by DNA lacking the CpG motif and present in a mycobacterial cell wall complex","volume":"49","author":"Filion","year":"2000","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.urolonc.2015.12.004_bib21","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.juro.2008.11.019","article-title":"Intravesical mycobacterial cell wall-DNA complex in the treatment of carcinoma in situ of the bladder after standard intravesical therapy has failed","volume":"181","author":"Morales","year":"2009","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2015.12.004_bib22","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/j.juro.2014.09.109","article-title":"Efficacy and safety of MCNA in patients with non\u2013muscle invasive bladder cancer at high-risk of recurrence and progression who have failed treatment with Bacillus Calmette-Guerin","volume":"193","author":"Morales","year":"2015","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2015.12.004_bib23","first-page":"9","article-title":"Amaromycin, a new antibiotic from Streptomyces","volume":"8","author":"Hata","year":"1955","journal-title":"J Antibiot"},{"key":"10.1016\/j.urolonc.2015.12.004_bib24","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/S0022-5347(01)65673-8","article-title":"A randomized multicenter trial of adjuvant therapy in superficial bladder cancer: transurethral resection only versus transurethral resection plus mitomycin C versus transurethral resection plus Bacillus Calmette-Guerin. Participating clinics","volume":"156","author":"Krege","year":"1996","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2015.12.004_bib25","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/S0022-5347(01)67608-0","volume":"153","author":"Bouffioux","year":"1995","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2015.12.004_bib26","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.urology.2003.11.049","article-title":"Intravesical Bacille Calmette-Guerin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression","volume":"63","author":"Bohle","year":"2004","journal-title":"Urology"},{"key":"10.1016\/j.urolonc.2015.12.004_bib27","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/S0022-5347(05)64043-8","article-title":"Intravesical Bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity","volume":"169","author":"Bohle","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2015.12.004_bib28","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0022-5347(01)61607-0","article-title":"5-year follow-up of a randomized prospective study comparing mitomycin C and acillus Calmette-Guerin in patients with superficial bladder carcinoma. Swedish-Norwegian bladder cancer study group","volume":"161","author":"Malmstr\u00f6m","year":"1999","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2015.12.004_bib30","unstructured":"Eli Lilly and Company. Gemzar (gemcitabine for injection, USP). [Package Insert] 2014 [cited 2014 September 18, 2014]; http:\/\/www.gemzar.com."},{"key":"10.1016\/j.urolonc.2015.12.004_bib31","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S0959-8049(98)00030-6","article-title":"A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Italian co-operative group on bladder cancer","volume":"34","author":"Lorusso","year":"1998","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.urolonc.2015.12.004_bib32","doi-asserted-by":"crossref","first-page":"3394","DOI":"10.1200\/JCO.1997.15.11.3394","article-title":"Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer","volume":"15","author":"Stadler","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2015.12.004_bib33","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1111\/j.1464-410X.2003.04656.x","article-title":"Intravesical administration of gemcitabine in superficial bladder cancer: a phase I study with pharmacodynamic evaluation","volume":"93","author":"De Berardinis","year":"2004","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2015.12.004_bib34","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1200\/JCO.2003.09.028","article-title":"Intravesical gemcitabine therapy for superficial transitional cell carcinoma of the bladder: a phase I and pharmacokinetic study","volume":"21","author":"Laufer","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2015.12.004_bib35","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.1200\/JCO.2002.02.066","article-title":"Phase I trial of intravesical gemcitabine in Bacillus Calmette-Guerin-refractory transitional-cell carcinoma of the bladder","volume":"20","author":"Dalbagni","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2015.12.004_bib36","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.urology.2005.04.062","article-title":"Intravesical gemcitabine therapy for superficial transitional cell carcinoma: results of a Phase II prospective multicenter study","volume":"66","author":"Bartoletti","year":"2005","journal-title":"Urology"},{"key":"10.1016\/j.urolonc.2015.12.004_bib37","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.urolonc.2007.10.016","article-title":"Intravesicle gemcitabine in management of BCG refractory superficial TCC of urinary bladder\u2014our experience","volume":"26","author":"Mohanty","year":"2008","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urolonc.2015.12.004_bib38","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1111\/j.1464-410X.2005.05739.x","article-title":"Intravesical gemcitabine for superficial bladder cancer: rationale for a new treatment option","volume":"96","author":"Gontero","year":"2005","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2015.12.004_bib39","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/j.juro.2013.04.031","article-title":"SWOG S0353: phase II trial of intravesical gemcitabine in patients with nonmuscle invasive bladder cancer and recurrence after 2 prior courses of intravesical Bacillus Calmette-Guerin","volume":"190","author":"Skinner","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2015.12.004_bib40","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1002\/cncr.24914","article-title":"Gemcitabine versus Bacille Calmette-Guerin after initial Bacille Calmette-Guerin failure in non-muscle-invasive bladder cancer: a multicenter prospective randomized trial","volume":"116","author":"Di Lorenzo","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.urolonc.2015.12.004_bib41","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/978-3-642-81565-2_2","article-title":"Preclinical rationale and phase I clinical trial of the adriamycin analog, AD 32","volume":"76","author":"Blum","year":"1981","journal-title":"Recent Results Cancer Res"},{"key":"10.1016\/j.urolonc.2015.12.004_bib42","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/BF00296255","article-title":"Effects of N-trifluoroacetyladriamycin-14-valerate (AD-32) on human bladder tumor cell lines","volume":"19","author":"Niell","year":"1987","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.urolonc.2015.12.004_bib43","first-page":"364","article-title":"Drug penetration into dog bladder wall following intravesical (ive) instillation of N-trifluoroacetyladriamycin-14-valerate (AD 32). in Proc","volume":"34","author":"Sweatman","year":"1993","journal-title":"Am Assoc Cancer Res"},{"key":"10.1016\/j.urolonc.2015.12.004_bib44","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/S0090-4295(96)00621-8","article-title":"Initial report on intravesical administration of N-trifluoroacetyladriamycin-14-valerate (AD 32) to patients with refractory superficial transitional cell carcinoma of the urinary bladder","volume":"49","author":"Greenberg","year":"1997","journal-title":"Urology"},{"key":"10.1016\/j.urolonc.2015.12.004_bib45","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S0022-5347(05)67799-3","article-title":"Efficacy and safety of valrubicin for the treatment of Bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. The valrubicin study group","volume":"163","author":"Steinberg","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2015.12.004_bib46","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.urolonc.2008.05.004","article-title":"Phase II study of intravesical therapy with AD32 in patients with papillary urothelial carcinoma or carcinoma in situ (CIS) refractory to prior therapy with Bacillus Calmette-Guerin (E3897): a trial of the Eastern cooperative oncology group","volume":"27","author":"Ignatoff","year":"2009","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urolonc.2015.12.004_bib47","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/S0149-2918(00)89011-6","article-title":"Management of patients with Bacilli Calmette-Guerin-refractory carcinoma in situ of the urinary bladder: cost implications of a clinical trial for valrubicin","volume":"22","author":"Marchetti","year":"2000","journal-title":"Clin Ther"},{"key":"10.1016\/j.urolonc.2015.12.004_bib48","unstructured":"Sanofi-Aventis US LLC. Taxotere. [Package Insert] 2013 [cited 2014 September 18, 2014]; http:\/\/products.sanofi.us\/Taxotere\/taxotere.html."},{"key":"10.1016\/j.urolonc.2015.12.004_bib49","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1007\/BF00686501","article-title":"Taxol and taxotere in bladder cancer: in vitro activity and urine stability","volume":"33","author":"Rangel","year":"1994","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.urolonc.2015.12.004_bib50","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.1200\/JCO.2005.03.1161","article-title":"Phase I trial of intravesical docetaxel in the management of superficial bladder cancer refractory to standard intravesical therapy","volume":"24","author":"McKiernan","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2015.12.004_bib51","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.juro.2012.10.068","article-title":"Long-term survival outcomes with intravesical docetaxel for recurrent nonmuscle invasive bladder cancer after previous Bacillus Calmette-Guerin therapy","volume":"189","author":"Barlow","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2015.12.004_bib52","doi-asserted-by":"crossref","first-page":"4136","DOI":"10.1158\/1078-0432.CCR-04-2291","article-title":"Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol)","volume":"11","author":"Sparreboom","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.urolonc.2015.12.004_bib53","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.juro.2011.03.129","article-title":"A phase I trial of intravesical nanoparticle albumin-bound paclitaxel in the treatment of Bacillus Calmette-Guerin refractory nonmuscle invasive bladder cancer","volume":"186","author":"McKiernan","year":"2011","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2015.12.004_bib54","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1016\/j.juro.2014.06.084","article-title":"Phase II trial of intravesical nanoparticle albumin bound paclitaxel for the treatment of nonmuscle invasive urothelial carcinoma of the bladder after Bacillus Calmette-Guerin treatment failure","volume":"192","author":"McKiernan","year":"2014","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2015.12.004_bib55","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1097\/01.ju.0000150425.09317.67","article-title":"Bacillus Calmette-Guerin versus epirubicin for primary, secondary or concurrent carcinoma in situ of the bladder: results of a European organization for the research and treatment of cancer--genito-urinary group phase iii trial (30906)","volume":"173","author":"de Reijke","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2015.12.004_bib56","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1111\/j.1442-2042.2005.01064.x","article-title":"Twelve-year follow up of a randomized prospective trial comparing Bacillus Calmette-Guerin and epirubicin as adjuvant therapy in superficial bladder cancer","volume":"12","author":"Cheng","year":"2005","journal-title":"Int J Urol"},{"key":"10.1016\/j.urolonc.2015.12.004_bib57","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.eururo.2009.12.024","volume":"57","author":"Sylvester","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2015.12.004_bib58","series-title":"J Urol","article-title":"Intravesical sequential gemcitabine-mitomycin chemotherapy as salvage treatment for patients with refractory superficial bladder cancer","author":"Maymi","year":"2006"},{"key":"10.1016\/j.urolonc.2015.12.004_bib59","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.urolonc.2008.11.019","article-title":"Sequential intravesical gemcitabine and mitomycin C chemotherapy regimen in patients with non-muscle invasive bladder cancer","volume":"28","author":"Breyer","year":"2010","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urolonc.2015.12.004_bib60","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.urolonc.2013.01.009","article-title":"Multi-institutional analysis of sequential intravesical gemcitabine and mitomycin C chemotherapy for non-muscle invasive bladder cancer","volume":"32","author":"Lightfoot","year":"2014","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urolonc.2015.12.004_bib61","first-page":"4","article-title":"Supply and demand: dealing with drug shortages, in global connections","author":"Holzbeierlein","year":"2013","journal-title":"Am Urolo Assoc"},{"key":"10.1016\/j.urolonc.2015.12.004_bib62","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.eururo.2004.06.009","article-title":"The effect of hyperthermia on mitomycin-C induced cytotoxicity in four human bladder cancer cell lines","volume":"46","author":"van der Heijden","year":"2004","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2015.12.004_bib63","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1016\/j.juro.2009.06.017","article-title":"Combined thermo-chemotherapy for recurrent bladder cancer after Bacillus Calmette-Guerin","volume":"182","author":"Nativ","year":"2009","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2015.12.004_bib64","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s00345-009-0384-2","article-title":"Intravesical hyperthermia and mitomycin-C for carcinoma in situ of the urinary bladder: experience of the European Synergo\u00ae working party","volume":"27","author":"Witjes","year":"2009","journal-title":"World J Urol"},{"key":"10.1016\/j.urolonc.2015.12.004_bib65","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/iju.12639","article-title":"Is thermochemotherapy with the Synergo system a viable treatment option in patients with recurrent non-muscle-invasive bladder cancer?","volume":"22","author":"Kiss","year":"2015","journal-title":"Int J Urol"},{"key":"10.1016\/j.urolonc.2015.12.004_bib66","first-page":"4912","article-title":"Electromotive versus passive diffusion of mitomycin c into human bladder wall concentration-depth profiles studies","volume":"59","author":"Di Stasi","year":"1999","journal-title":"Cancer Res"},{"key":"10.1016\/j.urolonc.2015.12.004_bib67","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1097\/01.ju.0000080568.91703.18","article-title":"Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: a prospective randomized study","volume":"170","author":"Di Stasi","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2015.12.004_bib68","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1016\/S0022-5347(05)00701-9","article-title":"Photodynamic therapy for urological malignancies: past to current approaches","volume":"175","author":"Pinthus","year":"2006","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2015.12.004_bib69","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1056\/NEJM198711123172003","article-title":"Photodynamic therapy with hematoporphyrin derivative in the treatment of superficial transitional-cell carcinoma of the bladder","volume":"317","author":"Prout","year":"1987","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2015.12.004_bib70","doi-asserted-by":"crossref","first-page":"3113","DOI":"10.1002\/1097-0142(19871215)60:12<3113::AID-CNCR2820601242>3.0.CO;2-2","article-title":"Photodynamic therapy in the management of resistant lower urinary tract carcinoma","volume":"60","author":"Nseyo","year":"1987","journal-title":"Cancer"},{"key":"10.1016\/j.urolonc.2015.12.004_bib71","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/bjc.1995.122","article-title":"Whole bladder wall photodynamic therapy for refractory carcinoma in situ of the bladder","volume":"71","author":"Uchibayashi","year":"1995","journal-title":"Br J Cancer"},{"key":"10.1016\/j.urolonc.2015.12.004_bib72","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0022-5347(01)63021-0","article-title":"Photodynamic therapy using porfimer sodium as an alternative to cystectomy in patients with refractory transitional cell carcinoma in situ of the bladder. Bladder photofrin study group","volume":"160","author":"Nseyo","year":"1998","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2015.12.004_bib73","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/S0090-4295(02)02123-4","article-title":"Photodynamic therapy with intravesical instillation of 5-aminolevulinic acid for patients with recurrent superficial bladder cancer: a single-center study","volume":"61","author":"Berger","year":"2003","journal-title":"Urology"},{"key":"10.1016\/j.urolonc.2015.12.004_bib74","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1016\/j.urolonc.2012.02.007","article-title":"Photodynamic therapy of bladder cancer\u2014a phase I study using hexaminolevulinate (HAL)","volume":"31","author":"Bader","year":"2013","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urolonc.2015.12.004_bib75","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/j.juro.2013.04.077","article-title":"Efficacy and safety of photodynamic therapy for recurrent, high grade nonmuscle invasive bladder cancer refractory or intolerant to Bacille Calmette-Guerin immunotherapy","volume":"190","author":"Lee","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2015.12.004_bib76","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1200\/JCO.2006.05.8149","article-title":"Radiochemotherapy after transurethral resection for high-risk T1 bladder cancer: an alternative to intravesical therapy or early cystectomy?","volume":"24","author":"Weiss","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2015.12.004_bib77","unstructured":"Southern Illinois University and Merck Sharp & Dohme Corp. MK-3475\/BCG in High Risk Superficial Bladder Cancer (MARC). In: Clinicaltrials.gov [Internet] 2015 [September 1, 2015]; https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02324582?term=bladder+cancer+pembrolizumab&rank=1."}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143915005827?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143915005827?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:08:08Z","timestamp":1761041288000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143915005827"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6]]},"references-count":76,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["S1078143915005827"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2015.12.004","relation":{},"ISSN":["1078-1439"],"issn-type":[{"type":"print","value":"1078-1439"}],"subject":[],"published":{"date-parts":[[2016,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intravesical and alternative bladder-preservation therapies in the management of non\u2013muscle-invasive bladder cancer unresponsive to bacillus Calmette-Gu\u00e9rin","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2015.12.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}